5M Biomedical

Industry: Liquid biopsy for neurodegenerative diseases

5M Biomedical, out of Emory, is developing a non-invasive way to diagnose Alzheimer’s and related diseases. 

5M’s technology can reveal important biomarkers from a simple blood sample. Coupling anti-fouling agents with magnetic nanoparticles allows the biomarkers to be separated from the sample, drastically reducing the overall cost of diagnosis by simplifying the process.

The technology opens up possibilities for early detection of Alzheimer’s, which is increasingly important for the world’s aging population. With a compound growth rate of 38% annually, the global market for liquid biopsy technology is growing rapidly.

Company website: 5M Biomedical

Back to companies